TO: Iowa Public Department of Health

FROM: Heather Adams, Assistant Attorney General

Date: October 28, 2009

RE:  Public Readiness and Emergency Preparedness (PREP) Act for H1N1 Vaccination and Emergency Use Authorizations (EUAs) for H1N1 Countermeasures

Top News arrow AHRP Speaks Out
AHRP Speaks Out
Comments on AHRP Amicus Brief (Kennedy Krieger) Print E-mail
Monday, 01 October 2001

Following the August 16, 2001 landmark decision of the Maryland Court of Appeals, the Alliance for Human Research Protection (AHRP) became interested in the case involving exposure of children to lead paint. We were particularly drawn to the Court's clear and unambiguous recognition of the rights of children and their families to appropriate safeguards in medical research settings.

The Scientist News reports on AHRP as New Advocacy Group to Police Human Research Print E-mail
Monday, 20 August 2001

A group of patient and social justice advocates plan to form an Alliance for Human Research Protection to provide oversight on clinical research from laypersons' point of view, says John H. Noble Jr., a founder and professor of social justice at the Catholic University of America. He lambastes Internal Review Boards (IRBs) designed to protect human subjects as agents of institutions "who are hustling the bucks" from industry and other sources. Noble says IRBs need to be "severed from research institutions" and provided adequate resources as part of the accepted overhead costs of conducting clinical trials.

AHRP Comments on Landmark Decision by the Court of Appeals of Maryland Print E-mail
Monday, 20 August 2001

A landmark decision by Maryland's highest court, the Court of Appeals of Maryland, is a victory for the human rights of children. The decision affirms the responsibility of parents, the government, researchers and institutional review boards (IRB) to protect children from non-therapeutic experiments that may put their health at risk.

FDA: Regulatory Protections for Children Print E-mail
Monday, 06 August 2001

Comments submitted by Vera Hassner Sharav, John H. Noble, Jr., Ph.D and Howard Fishman, MEd, MSW for AHRP

To: Dr. Bernard Schwetz Acting Commissioner Food and Drug Administration, Dockets Management Branch (HFA-305) Food and Drug Administration

Re: COMMENT ON: Docket #00N-0074 April 24, 2001 Interim Rule: "Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products

Excerpt: The FDA rightly chose not to permit the section 46.408 (c) waiver by IRBs of parental or guardian permission, as it leaves the specific circumstances for such a violation of parental rights to the discretion of local Institutional Review Boards (IRB). Given the stream of revelations of gross ethical and procedural violations at one after another of the nation's premier research institutions, assumptions that "procedural safeguards are in place," or that IRBs can be relied upon to make decisions that protect the best interests of human subjects - adults and children - has been debunked.

Dissenting Opinion: Against Waiving Parental Permission for Research Print E-mail
Wednesday, 25 July 2001

To: Mary Faith Marshall, Ph.D, Chairperson, National Human Research Protections Advisory Committee, Department of Health and Human Services

Re: Specific Comment on FDA's Decision to Adopt HHS 45 CFR 46 Subpart D, EXCLUDING §46.408 (c)

Dissenting opinion of Vera Hassner Sharav, Founder and President, AHRP: Alliance for Human Research Protection, member, Children's Workgroup of the National Human Research Protections Advisory Committee, Department of Health and Human Services (HHS)

This dissenting opinion reflects the position of AHRP and was prepared in collaboration with Howard Fishman, M.S. W., M.Ed, and John H. Noble, Jr., PhD, AHRP board members.

Testimony Re: Research Involving Children Print E-mail
Thursday, 05 April 2001

Submitted to the Office of Human Research Protection
by Vera Hassner Sharav and Marie M. Cassidy, Ph.D, D.Sc.

AHRP recognizes that to include children in clinical trials for any medication presents a dilemma of truly Solomonic proportions. It is a choice between continuing the practice of prescribing untested drugs for children, as is currently the operational system, or conducting meaningful trials to determine both safety and effectiveness.

Chemically Induced Psychosis Experiments: An Inhumane Paradigm in Psychiatric Research Print E-mail
Wednesday, 02 February 2000

Congressional Testimony submitted by Vera Sharav

Statement For the Record Submitted to
The U.S. Senate Sub-Committee: Public Health & Safety of the Senate Health, Education, Labor & Pensions Committee Hearing

Our efforts helped bring to public attention major medical ethics violations in Federally-funded research in which uninformed, vulnerable American citizens are put at high risks without justification. As a result, such individuals have often suffered severe consequences - some have lost their lives unnecessarily. Based on the evidence - including testimonies by families and patients - we believe five factors contribute to unethical human experiments:

Evidence of Neuroleptic Drug-Induced Brain Damage in Patients Print E-mail
Monday, 31 January 2000

A partial, Annotated Bibliography by Vera Hassner Sharav

For distribution: January, 2000

Although patients, families and the public were not informed - some would argue they were deceived - clinical psychiatrists and researchers have long known about severe adverse drug reactions (ADR) and disabling changes in the central nervous system in a high percentage of patients taking standard neuroleptic drugs.

<< Start < Prev 1 2 3 4 5 Next > End >>

Results 41 - 48 of 48
(C) 2015 Alliance for Human Research Protection

General Terms & Disclaimer:

This site is not a monologue of truth. It is a catalyst for public debate about medical research conduct. The reader is urged to confront officials to clarify issues mentioned herein. This site is designed strictly to provide information for critical, literary, academic an public usage. A qualified and trustworthy medical professional must be consulted regarding medical issues, treatments, diagnoses, etc.

Please read the General Terms and Conditions of this agreement entirely and carefully before accessing this web site. By accessing the site, you agree to be bound by the terms and conditions listed herein. [continue]